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Background
The pharmacological treatment approach for juvenile
idiopathic arthritis (JIA) has changed substantially since
the introduction of biologicals, with nowadays inactive
disease as realistic treatment goal.
Aim
To identify factors at baseline which predict etanercept
treatment response and subsequently optimize treatment
strategies.
Methods
The Arthritis and Biologicals in Children Register
(observational study, ongoing since 1999), includes all
Dutch JIA-patients who used etanercept. Disease activity
variables were retrieved prospectively at start of treat-
ment, after 3 months, and yearly thereafter.
Results
262 previously biologic-naive JIA-patients initiated eta-
nercept; 71% female, 18% systemic-onset subtype. Med-
ian age at onset 6.9 (IQR 3.6-11.1) years, median follow-
up 35.6 (IQR 17.4-53.6) months. In the long-term, the
overall majority responded to etanercept and up to 40%
reached inactive disease. Excellent response after 15
months (85 patients, 32%) was associated with low base-
line disability (OR 0.49/point increase, 95%CI 0.33-0.74),
fewer DMARDs used before etanercept (OR 0.64/
DMARD used, 95%CI 0.43-0.95) and younger age at
onset (OR 0.92/year, 95%CI 0.84-0.99); poor response
(88 patients, 34%) was associated with female gender
(OR 2.12, 95%CI 1.11-4.08) and systemic-onset subtype
(OR 3.24, 95%CI 1.39-7.56). However, 24% of systemic-
onset patients reached excellent response. Reasons for
discontinuation: ineffectiveness in 78, adverse events
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well tolerated. Patients who developed AEs could not be
identified at baseline.
Conclusions
Excellent response was associated with baseline low dis-
ability and less DMARD-use before etanercept. There-
fore, the focus should be on strategies with early
introduction of etanercept to improve outcomes for JIA.
The role of etanercept for the systemic-onset subtype
remains debatable.
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